(HealthDay)—For patients with active ankylosing spondylitis, secukinumab is associated with reductions in symptoms at week 16, according to a study published in the Dec. 24 issue of the New England Journal of Medicine.
Dec 24, 2015
0
35
(HealthDay)—Secukinumab is safe and effective as a treatment for patients with extensive moderate-to-severe scalp psoriasis, according to a study published in the October issue of the Journal of the American Academy of ...
Sep 29, 2017
0
0
The difference in effect of two drugs commonly used to treat psoriasis was reliably reproduced from a clinical trial by a large observational study carried out by University of Manchester and Salford Royal NHS Foundation ...
Dec 10, 2020
1
1
(HealthDay)—Among biologics used for the treatment of psoriasis, there do not appear to be differential risks for serious infection or respiratory tract infection, according to a study presented at the annual meeting of ...
Oct 8, 2021
0
3
Secukinumab (trade name: Cosentyx) has been approved since January 2015 for adults with moderate to severe plaque psoriasis. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment ...
Sep 8, 2015
0
2
